Yong‐Jun Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yong‐Jun Wang has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Yi‐Long Wang
Department of Neurology Beijing Tiantan Hospital Capital Medical University Beijing China
8 shared publicationsChun‐Xue Wang
Department of Neurology Beijing Tiantan Hospital Capital Medical University Beijing China
7 shared publicationsLi‐Ping Liu
Department of Neurology Beijing Tiantan Hospital Capital Medical University Beijing China
7 shared publicationsXing‐Quan Zhao
Department of Neurology Beijing Tiantan Hospital Capital Medical University Beijing China
7 shared publicationsGai‐Fen Liu
Department of Neurology Beijing Tiantan Hospital Affiliated to Capital Medical University Beijing China
5 shared publicationsAn‐Xin Wang
Department of Neurology Beijing Tiantan Hospital Capital Medical University Beijing China
4 shared publications
Latest Publications
- 5 April 2013
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 126 (7) , 1236-1241
In-hospital medical complications associated with patient dependency after acute ischemic stroke: data from the China National Stroke Registry
Background: The mortality of stroke patients is strongly affected by medical complications. However, there are limited data investigating the effect of in-hospital medical complications on the dependency of stroke patients worldwide. We prospectively and systematically investigated the effect of medical complications on dependency of patients at 3, 6 and 12 months after stroke using the China National Stroke Registry (CNSR). Methods: This prospective cohort study collected data of patients age >18 years with acute ischemic stroke in 132 clinical centers distributed across 32 provinces and four municipalities (including Hong Kong region) of China, from September 2007 to August 2008. Data on medical complications, dependency and other information were obtained from paper-based registry forms. Medical complications associated with stroke outcomes were assessed using multivariable Logistic regression. Results: Of 11 560 patients with acute ischemic stroke, 1826 (15.80%) presented with in-hospital medical complications. In-hospital medical complications were independent risk factors for dependency of patients at 3 months (adjusted odds ratio (OR) 2.367, 95% confidence interval (CI) 2.021-2.771), 6 months (adjusted OR 2.257, 95% CI 1.922-2.650), and 12 months (adjusted OR 1.820, 95% CI 1.538-2.154) after acute ischemic stroke. Conclusion: The results demonstrated that the short-term and long-term dependency of acute ischemic stroke patients is significantly associated with in-hospital medical complications in China.
- 5 April 2013
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 126 (7) , 1236-1241
In-hospital medical complications associated with patient dependency after acute ischemic stroke: data from the China National Stroke Registry
Background: The mortality of stroke patients is strongly affected by medical complications. However, there are limited data investigating the effect of in-hospital medical complications on the dependency of stroke patients worldwide. We prospectively and systematically investigated the effect of medical complications on dependency of patients at 3, 6 and 12 months after stroke using the China National Stroke Registry (CNSR). Methods: This prospective cohort study collected data of patients age >18 years with acute ischemic stroke in 132 clinical centers distributed across 32 provinces and four municipalities (including Hong Kong region) of China, from September 2007 to August 2008. Data on medical complications, dependency and other information were obtained from paper-based registry forms. Medical complications associated with stroke outcomes were assessed using multivariable Logistic regression. Results: Of 11 560 patients with acute ischemic stroke, 1826 (15.80%) presented with in-hospital medical complications. In-hospital medical complications were independent risk factors for dependency of patients at 3 months (adjusted odds ratio (OR) 2.367, 95% confidence interval (CI) 2.021-2.771), 6 months (adjusted OR 2.257, 95% CI 1.922-2.650), and 12 months (adjusted OR 1.820, 95% CI 1.538-2.154) after acute ischemic stroke. Conclusion: The results demonstrated that the short-term and long-term dependency of acute ischemic stroke patients is significantly associated with in-hospital medical complications in China.
- Open Access
- 18 January 2013
- Published by Springer Nature
Imaging-based Thrombolysis Trial in Acute Ischemic Stroke
- 18 January 2013
- Published by Springer Nature
Open AccessImaging-based Thrombolysis Trial in Acute Ischemic Stroke
- 26 December 2012
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 19 (2) , 142-144
Persistence with Antihypertensive Agents for 12 Months After Ischemic Stroke Reduces the Rates of Death and Dependency
- 26 December 2012
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 19 (2) , 142-144
Persistence with Antihypertensive Agents for 12 Months After Ischemic Stroke Reduces the Rates of Death and Dependency
- Open Access
- 6 December 2012
- Published by Springer Nature
Thrombolysis Register of Acute Ischaemic Stroke in China
- 6 December 2012
- Published by Springer Nature
Open AccessThrombolysis Register of Acute Ischaemic Stroke in China
- Open Access
- 29 November 2012
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 18 (12) , 1003-1011
Circulating MicroRNAs as Potential Risk Biomarkers for Hematoma Enlargement after Intracerebral Hemorrhage
Summary: Background and Purpose: MicroRNAs have recently been shown to regulate the downstream bioprocesses of intracerebral hemorrhage. The aim of this study was to investigate whether miRNAs can be used as biomarkers to predict secondary hematoma enlargement (HE) in patients with ICH.Methods: Consecutively, 79 ICH patients admitted within 6 h of symptom onset and 30 healthy individuals were enrolled in this study. Whole‐genome miRNA expression profiles were generated in 32 patients (HE/non‐HE: 14/18). Representative differentially expressed miRNAs were measured in all cases (HE/non‐HE: 30/49) and normal controls (n = 30) by real‐time PCR.Results: Thirty miRNAs showed differential expressions in the plasma samples from patients with HE as compared with the non‐HE controls. Compared to the hierarchical cluster analysis with all probes on microarray, all patients were separated into two main branches with only four exceptions by 30 differentially expressed miRNAs, improving the overall accuracy from 47.62 to 77.78% in the HE and 72.73 to 100% in the non‐HE group. Further support vector machine (SVM) test can discriminate the two groups with 100% accuracy with 10 differentially expressed miRNAs.Conclusions: We demonstrated that multiple miRNAs are differentially expressed in the plasma of ICH patients with or without HE and may serve as circulating biomarkers for predicting HE after ICH.
- 29 November 2012
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 18 (12) , 1003-1011
Open AccessCirculating MicroRNAs as Potential Risk Biomarkers for Hematoma Enlargement after Intracerebral Hemorrhage
Summary: Background and Purpose: MicroRNAs have recently been shown to regulate the downstream bioprocesses of intracerebral hemorrhage. The aim of this study was to investigate whether miRNAs can be used as biomarkers to predict secondary hematoma enlargement (HE) in patients with ICH.Methods: Consecutively, 79 ICH patients admitted within 6 h of symptom onset and 30 healthy individuals were enrolled in this study. Whole‐genome miRNA expression profiles were generated in 32 patients (HE/non‐HE: 14/18). Representative differentially expressed miRNAs were measured in all cases (HE/non‐HE: 30/49) and normal controls (n = 30) by real‐time PCR.Results: Thirty miRNAs showed differential expressions in the plasma samples from patients with HE as compared with the non‐HE controls. Compared to the hierarchical cluster analysis with all probes on microarray, all patients were separated into two main branches with only four exceptions by 30 differentially expressed miRNAs, improving the overall accuracy from 47.62 to 77.78% in the HE and 72.73 to 100% in the non‐HE group. Further support vector machine (SVM) test can discriminate the two groups with 100% accuracy with 10 differentially expressed miRNAs.Conclusions: We demonstrated that multiple miRNAs are differentially expressed in the plasma of ICH patients with or without HE and may serve as circulating biomarkers for predicting HE after ICH.
- Open Access
- 2 November 2012
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 18 (12) , 988-993
One‐year Clinical Prediction in Chinese Ischemic Stroke Patients Using the CHADS2 and CHA2DS2‐VASc Scores: The China National Stroke Registry
Summary: Aims: We investigated whether CHADS2 or CHA2DS2‐VASc scores could be used to predict 1‐year prognosis in stroke recurrence, mortality, and mortality of ischemic stroke or transient ischemic attack (TIA) patients with nonvalvular atrial fibrillation (NVAF).Methods: Patients were selected from a national prospective registry in China. The clinical prediction of the scores was examined using the C statistic. Univariate and multivariate logistic regressions were performed to analyze the relevant risk factors.Results: Thousand two hundred and ninety‐seven of 22,216 patients were enrolled in the study. For stroke recurrence rate, the C statistic value was 0.53 (odds ratio [OR] 1.15, 95% confidence interval [CI]: 1.01 to 1.32) for CHADS2 and 0.55 (OR 1.14, 95% CI: 1.05 to 1.24) for CHA2DS2‐VASc; adding baseline National Institutes of Health Stroke Scale (NIHSS) score to these two scores, the value of C statistic was 0.58 (OR 1.25 95% CI: 1.14 to 1.37) and 0.58 (OR 1.19, 95% CI: 1.11 to 1.27), respectively.Conclusions: Both CHADS2 and CHA2DS2‐VASc scores have limitations in predicting the 1‐year prognosis of stroke/TIA patients with NVAF in China. The predictive value of these two scores improved by adding the baseline NIHSS score.
- 2 November 2012
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 18 (12) , 988-993
Open AccessOne‐year Clinical Prediction in Chinese Ischemic Stroke Patients Using the CHADS2 and CHA2DS2‐VASc Scores: The China National Stroke Registry
Summary: Aims: We investigated whether CHADS2 or CHA2DS2‐VASc scores could be used to predict 1‐year prognosis in stroke recurrence, mortality, and mortality of ischemic stroke or transient ischemic attack (TIA) patients with nonvalvular atrial fibrillation (NVAF).Methods: Patients were selected from a national prospective registry in China. The clinical prediction of the scores was examined using the C statistic. Univariate and multivariate logistic regressions were performed to analyze the relevant risk factors.Results: Thousand two hundred and ninety‐seven of 22,216 patients were enrolled in the study. For stroke recurrence rate, the C statistic value was 0.53 (odds ratio [OR] 1.15, 95% confidence interval [CI]: 1.01 to 1.32) for CHADS2 and 0.55 (OR 1.14, 95% CI: 1.05 to 1.24) for CHA2DS2‐VASc; adding baseline National Institutes of Health Stroke Scale (NIHSS) score to these two scores, the value of C statistic was 0.58 (OR 1.25 95% CI: 1.14 to 1.37) and 0.58 (OR 1.19, 95% CI: 1.11 to 1.27), respectively.Conclusions: Both CHADS2 and CHA2DS2‐VASc scores have limitations in predicting the 1‐year prognosis of stroke/TIA patients with NVAF in China. The predictive value of these two scores improved by adding the baseline NIHSS score.
- 29 October 2012
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 18 (11) , 942-944
Effects of Poststroke Hypertension and Hyperglycemia on Functional Outcomes in Stroke Patients Without History of Hypertension or Diabetes
- 29 October 2012
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 18 (11) , 942-944
Effects of Poststroke Hypertension and Hyperglycemia on Functional Outcomes in Stroke Patients Without History of Hypertension or Diabetes
- Open Access
- 5 September 2012
- Published by Springer Nature in BMC Neurology
- Vol. 12 (1) , 88
Rationale and design of a double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of nimodipine in preventing cognitive impairment in ischemic cerebrovascular events (NICE)
Stroke is the second most common cause of mortality and the leading cause of neurological disability, cognitive impairment and dementia worldwide. Nimodipine is a dihydropyridinic calcium antagonist with a role in neuroprotection, making it a promising therapy for vascular cognitive impairment and dementia. The NICE study is a multicenter, randomized, double-blind, placebo-controlled study being carried out in 23 centers in China. The study population includes patients aged 30–80 who have suffered an ischemic stroke (≤7 days). Participants are randomly allocated to nimodipine (90 mg/d) or placebo (90 mg/d). The primary efficacy is to evaluate the level of mild cognitive impairment following treatment of an ischemic stroke with nimodipine or placebo for 6 months. Safety is being assessed by observing side effects of nimodipine. Assuming a relative risk reduction of 22%, at least 656 patients are required in this study to obtain statistical power of 90%. The first patient was recruited in November 2010. Previous studies suggested that nimodipine could improve cognitive function in vascular dementia and Alzheimer’s disease dementia. It is unclear that at which time-point intervention with nimodipine should occur. Therefore, the NICE study is designed to evaluate the benefits and safety of nimodipine, which was adminstered within seven days, in preventing/treating mild cognitive impairment following ischemic stroke.
- 5 September 2012
- Published by Springer Nature in BMC Neurology
- Vol. 12 (1) , 88
Open AccessRationale and design of a double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of nimodipine in preventing cognitive impairment in ischemic cerebrovascular events (NICE)
Stroke is the second most common cause of mortality and the leading cause of neurological disability, cognitive impairment and dementia worldwide. Nimodipine is a dihydropyridinic calcium antagonist with a role in neuroprotection, making it a promising therapy for vascular cognitive impairment and dementia. The NICE study is a multicenter, randomized, double-blind, placebo-controlled study being carried out in 23 centers in China. The study population includes patients aged 30–80 who have suffered an ischemic stroke (≤7 days). Participants are randomly allocated to nimodipine (90 mg/d) or placebo (90 mg/d). The primary efficacy is to evaluate the level of mild cognitive impairment following treatment of an ischemic stroke with nimodipine or placebo for 6 months. Safety is being assessed by observing side effects of nimodipine. Assuming a relative risk reduction of 22%, at least 656 patients are required in this study to obtain statistical power of 90%. The first patient was recruited in November 2010. Previous studies suggested that nimodipine could improve cognitive function in vascular dementia and Alzheimer’s disease dementia. It is unclear that at which time-point intervention with nimodipine should occur. Therefore, the NICE study is designed to evaluate the benefits and safety of nimodipine, which was adminstered within seven days, in preventing/treating mild cognitive impairment following ischemic stroke.
- 20 August 2012
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 18 (10) , 819-826
Age Differences in Clinical Characteristics, Health care, and Outcomes after Ischemic Stroke in China
Summary: Background and purpose: Little information is available on the effects of age on health care and outcomes of ischemic stroke (IS) in China. Our aim was to evaluated risk factors, health care, and outcomes among age groups including ≤45, 46–65, 66–79, and ≥80 years and to find whether the outcome was affected by age and health care.Methods: CNSR is a nationwide prospective registry for patients admitted with acute stroke and prospectively followed up 12‐month outcomes. Demographics, socioeconomics, risk factors, health care, and outcomes were analyzed among age groups, and multivariate regression analysis was used to determine the association of outcome and age and health care.Results: We identified 12,415 acute IS patients for analysis. Of 1179 (9.50%) were aged ≥80 years. In terms of risk factors, cardiac diseases were significantly more frequent in patients ≥80 years, behavioral risk factors were more common in younger patients, and hypertension, hyperlipidemia, and diabetes were more seen in 46–79 patients. The use of health care varied among groups and was significantly lower in ≥80 years especially in secondary prevention. The very old patients had the worst outcomes even after adjusting by prognostic factors; however, adjusting forward by health care, the extent of differences decreased.Conclusions: In CNSR, differences in stroke clinic characteristics and health care were observed among various age groups, and the old patients, receiving lower levels of stroke care, had the worst outcomes. Knowledge of the age differences in ischemic stroke may be helpful to appropriately allocate the limited health resources and to improve stroke outcomes.
- 20 August 2012
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 18 (10) , 819-826
Age Differences in Clinical Characteristics, Health care, and Outcomes after Ischemic Stroke in China
Summary: Background and purpose: Little information is available on the effects of age on health care and outcomes of ischemic stroke (IS) in China. Our aim was to evaluated risk factors, health care, and outcomes among age groups including ≤45, 46–65, 66–79, and ≥80 years and to find whether the outcome was affected by age and health care.Methods: CNSR is a nationwide prospective registry for patients admitted with acute stroke and prospectively followed up 12‐month outcomes. Demographics, socioeconomics, risk factors, health care, and outcomes were analyzed among age groups, and multivariate regression analysis was used to determine the association of outcome and age and health care.Results: We identified 12,415 acute IS patients for analysis. Of 1179 (9.50%) were aged ≥80 years. In terms of risk factors, cardiac diseases were significantly more frequent in patients ≥80 years, behavioral risk factors were more common in younger patients, and hypertension, hyperlipidemia, and diabetes were more seen in 46–79 patients. The use of health care varied among groups and was significantly lower in ≥80 years especially in secondary prevention. The very old patients had the worst outcomes even after adjusting by prognostic factors; however, adjusting forward by health care, the extent of differences decreased.Conclusions: In CNSR, differences in stroke clinic characteristics and health care were observed among various age groups, and the old patients, receiving lower levels of stroke care, had the worst outcomes. Knowledge of the age differences in ischemic stroke may be helpful to appropriately allocate the limited health resources and to improve stroke outcomes.
- 20 July 2012
- Vol. 125 (14) , 2449-2454
Effect of in-hospital medical complications on case fatality post-acute ischemic stroke: data from the China National Stroke Registry
Background In-hospital medical complications are associated with poorer clinical outcomes for stroke patients after disease onset. However, few studies from China have reported the effect of these complications on the mortality of patients with acute ischemic stroke. In this prospective work, the China National Stroke Registry Study, we investigated the effect of medical complications on the case fatality of patients with acute ischemic stroke. Methods From September 2007 to August 2008, we prospectively obtained the data of patients with acute stroke from 132 clinical centers in China. Medical complications, case fatality and other information recorded at baseline, during hospitalisation, and at 3, 6, and 12 months after stroke onset. Multivariable Logistic regression was performed to analyze the effect of medical complications on the case fatality of patients with acute ischemic stroke. Results There were 39 741 patients screened, 14 526 patients with acute ischemic stroke recruited, and 11 560 ischemic stroke patients without missing data identified during the 12-month follow-up. Of the 11 560 ischemic patients, 15.8% (1826) had in-hospital medical complications. The most common complication was pneumonia (1373; 11.9% of patients), followed by urinary tract infection and gastrointestinal bleeding. In comparison with patients without complications, stroke patients with complications had a significantly higher risk of death during their hospitalization, and at 3, 6 and 12 months post-stroke. Having any one in-hospital medical complication was an independent risk factor for death in patients with acute ischemic stroke during hospital period (adjusted OR=6.946; 95% CI 5.181 to 9.314), at 3 months (adjusted OR=3.843; 95% CI 3.221 to 4.584), 6 months (adjusted OR=3.492; 95% CI 2.970 to 4.106), and 12 months (adjusted OR= 3.511; 95% CI 3.021 to 4.080). Having multiple complications strongly increased the death risk of patients. Conclusion Short-term and long-term outcomes of acute stroke patients are affected by in-hospital medical complications. Chin Med J 2012;125(14):2449-2454
- 20 July 2012
- Vol. 125 (14) , 2449-2454
Effect of in-hospital medical complications on case fatality post-acute ischemic stroke: data from the China National Stroke Registry
Background In-hospital medical complications are associated with poorer clinical outcomes for stroke patients after disease onset. However, few studies from China have reported the effect of these complications on the mortality of patients with acute ischemic stroke. In this prospective work, the China National Stroke Registry Study, we investigated the effect of medical complications on the case fatality of patients with acute ischemic stroke. Methods From September 2007 to August 2008, we prospectively obtained the data of patients with acute stroke from 132 clinical centers in China. Medical complications, case fatality and other information recorded at baseline, during hospitalisation, and at 3, 6, and 12 months after stroke onset. Multivariable Logistic regression was performed to analyze the effect of medical complications on the case fatality of patients with acute ischemic stroke. Results There were 39 741 patients screened, 14 526 patients with acute ischemic stroke recruited, and 11 560 ischemic stroke patients without missing data identified during the 12-month follow-up. Of the 11 560 ischemic patients, 15.8% (1826) had in-hospital medical complications. The most common complication was pneumonia (1373; 11.9% of patients), followed by urinary tract infection and gastrointestinal bleeding. In comparison with patients without complications, stroke patients with complications had a significantly higher risk of death during their hospitalization, and at 3, 6 and 12 months post-stroke. Having any one in-hospital medical complication was an independent risk factor for death in patients with acute ischemic stroke during hospital period (adjusted OR=6.946; 95% CI 5.181 to 9.314), at 3 months (adjusted OR=3.843; 95% CI 3.221 to 4.584), 6 months (adjusted OR=3.492; 95% CI 2.970 to 4.106), and 12 months (adjusted OR= 3.511; 95% CI 3.021 to 4.080). Having multiple complications strongly increased the death risk of patients. Conclusion Short-term and long-term outcomes of acute stroke patients are affected by in-hospital medical complications. Chin Med J 2012;125(14):2449-2454